Literature DB >> 19414878

Improving quality and diffusing best practices: the case of schizophrenia.

Marcela Horvitz-Lennon1, Julie M Donohue, Marisa E Domino, Sharon-Lise T Normand.   

Abstract

The slow spread of treatments supported by empirical evidence and the rapid diffusion of treatments lacking such support play major roles in the lower quality of mental health care received by people with severe mental illnesses compared with the care of less severely ill people. Further, the rapid spread of treatments that are of low cost-effectiveness limits the system's ability to provide the full gamut of high-value treatments available to treat this vulnerable population. Using the case of schizophrenia, we review the context in which these paradoxical patterns of diffusion have occurred, and we propose policy solutions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414878      PMCID: PMC2832306          DOI: 10.1377/hlthaff.28.3.701

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  41 in total

1.  Effect of clozapine on polypharmacy.

Authors:  S A Chong; G J Remington; K Z Bezchlibnyk-Butler
Journal:  Psychiatr Serv       Date:  2000-02       Impact factor: 3.084

Review 2.  Implementing evidence-based practices for persons with severe mental illnesses.

Authors:  W C Torrey; R E Drake; L Dixon; B J Burns; L Flynn; A J Rush; R E Clark; D Klatzker
Journal:  Psychiatr Serv       Date:  2001-01       Impact factor: 3.084

3.  Process measures for the assessment and improvement of quality of care for schizophrenia.

Authors:  Richard C Hermann; Molly Finnerty; Scott Provost; R Heather Palmer; Jeff Chan; Greta Lagodmos; Terri Teller; Britt J Myrhol
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

4.  Implementation of evidence-based practices in state mental health systems: implications for research and effectiveness studies.

Authors:  Vijay Ganju
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

5.  Disseminating innovations in health care.

Authors:  Donald M Berwick
Journal:  JAMA       Date:  2003-04-16       Impact factor: 56.272

6.  Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Authors:  Todd P Gilmer; Christian R Dolder; David P Folsom; William Mastin; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

7.  Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.

Authors:  Eric Q Wu; Lizheng Shi; Howard Birnbaum; Teresa Hudson; Ronald Kessler
Journal:  Psychol Med       Date:  2006-08-15       Impact factor: 7.723

8.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

Authors:  Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

9.  Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia.

Authors:  Aileen B Rothbard; Eri Kuno; Kathy Foley
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

10.  The diffusion of new antipsychotic medications and formulary policy.

Authors:  Marisa Elena Domino; Richard G Frank; Robert Rosenheck
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  16 in total

1.  A web-based platform to support an evidence-based mental health intervention: lessons from the CBITS web site.

Authors:  Pamela Vona; Pete Wilmoth; Lisa H Jaycox; Janey S McMillen; Sheryl H Kataoka; Marleen Wong; Melissa E DeRosier; Audra K Langley; Joshua Kaufman; Lingqi Tang; Bradley D Stein
Journal:  Psychiatr Serv       Date:  2014-10-31       Impact factor: 3.084

2.  Patterns of Antipsychotic Prescribing by Physicians to Young Children.

Authors:  Haiden A Huskamp; Marcela Horvitz-Lennon; Ernst R Berndt; Sharon-Lise T Normand; Julie M Donohue
Journal:  Psychiatr Serv       Date:  2016-07-15       Impact factor: 3.084

3.  Where You Live Matters: Quality and Racial/Ethnic Disparities in Schizophrenia Care in Four State Medicaid Programs.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Rachel Garfield; Julie M Donohue; Judith R Lave; Sharon-Lise T Normand
Journal:  Health Serv Res       Date:  2015-03-11       Impact factor: 3.402

4.  The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.

Authors:  Marcela Horvitz-Lennon; Margarita Alegría; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2012-12       Impact factor: 3.084

5.  Use of a computerized medication shared decision making tool in community mental health settings: impact on psychotropic medication adherence.

Authors:  Bradley D Stein; Jane N Kogan; Mark J Mihalyo; James Schuster; Patricia E Deegan; Mark J Sorbero; Robert E Drake
Journal:  Community Ment Health J       Date:  2012-07-27

6.  Implementing a continuum of evidence-based psychosocial interventions for people with severe mental illness: part 2-review of critical implementation issues.

Authors:  Catherine Briand; Matthew Menear
Journal:  Can J Psychiatry       Date:  2014-04       Impact factor: 4.356

7.  Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage.

Authors:  Steve Offord; Jay Lin; Bruce Wong; Dario Mirski; Ross A Baker
Journal:  Community Ment Health J       Date:  2013-08-10

8.  Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Julie M Donohue; Judith R Lave; Bradley D Stein; Sharon-Lise T Normand
Journal:  Health Serv Res       Date:  2014-03-13       Impact factor: 3.402

9.  Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.

Authors:  Jay Lin; Bruce Wong; Steve Offord; Dario Mirski
Journal:  J Behav Health Serv Res       Date:  2013-07       Impact factor: 1.505

Review 10.  What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada?

Authors:  Richard Williams; Ashok Malla; Marc-Andre Roy; Ridha Joober; Rahul Manchanda; Phil Tibbo; Nicola Banks; Ofer Agid
Journal:  Can J Psychiatry       Date:  2016-07-09       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.